factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Probable | preserve | 515-523 | 515-523 | T29 | regulate | AFFECTS | 515 | 523 | preserve | 498-501 | 498-501 | T24 | COX | AminoAcidPeptideOrProtein | 498 | 501 | preserve | 536-557 | 548-557 | T26 | physiologic functions | PhysiologicFunction | 536 | 557 | A10 | COX-I appears to regulate many normal physiologic functions, and COX-2 mediates the inflammatory response. | 498-610 | 498 | 610 | @SUBJECT$ -I appears to @PREDICAT$ many normal @OBJECT$ , and COX-2 mediates the inflammatory response. |
Fact | preserve | 1249-1258 | 1249-1258 | T81 | treatment | TREATS | 1,249 | 1,258 | preserve | 1235-1241 | 1235-1241 | T71 | NSAIDs | PharmacologicSubstance | 1,235 | 1,241 | preserve | 1269-1289 | 1280-1289 | T73 | rheumatoid arthritis | DiseaseOrSyndrome | 1,269 | 1,289 | A11 | Celecoxib also has been shown to be as effective as traditional NSAIDs in the treatment of rheumatoid arthritis, but it may cause fewer adverse effects, including endoscopically documented ulcers. | 1164-1380 | 1,164 | 1,380 | Celecoxib also has been shown to be as effective as traditional @SUBJECT$ in the @PREDICAT$ of @OBJECT$ , but it may cause fewer adverse effects, including endoscopically documented ulcers. |
Counterfact | preserve | 710-719 | 710-719 | T41 | influence | AFFECTS | 710 | 719 | preserve | 629-634 | 629-634 | T30 | NSAID | PharmacologicSubstance | 629 | 634 | preserve | 727-754 | 745-754 | T35 | physiologic functions | PhysiologicFunction | 727 | 754 | A12 | Theoretically, an NSAID that inhibits COX-2 selectively should decrease inflammation but not influence normal physiologic functions and thus should cause fewer gastrointestinal side effects. | 611-813 | 611 | 813 | Theoretically, an @SUBJECT$ that inhibits COX-2 selectively should decrease inflammation but not @PREDICAT$ normal @OBJECT$ and thus should cause fewer gastrointestinal side effects. |
Probable | preserve | 680-688 | 680-688 | T40 | decrease | PREVENTS | 680 | 688 | preserve | 629-634 | 629-634 | T30 | NSAID | PharmacologicSubstance | 629 | 634 | preserve | 689-701 | 689-701 | T32 | inflammation | PathologicFunction | 689 | 701 | A13 | Theoretically, an NSAID that inhibits COX-2 selectively should decrease inflammation but not influence normal physiologic functions and thus should cause fewer gastrointestinal side effects. | 611-813 | 611 | 813 | Theoretically, an @SUBJECT$ that inhibits COX-2 selectively should @PREDICAT$ @OBJECT$ but not influence normal physiologic functions and thus should cause fewer gastrointestinal side effects. |
Fact | preserve | 415-465 | 415-424 | T22 | treatment of inflammation is the inhibition of COX | ISA | 415 | 465 | preserve | 462-465 | 462-465 | T20 | COX | AminoAcidPeptideOrProtein | 462 | 465 | preserve | 415-424 | 415-424 | T18 | treatment | TherapeuticOrPreventiveProcedure | 415 | 424 | A14 | The primary mechanism of NSAIDs in the treatment of inflammation is the inhibition of COX, which exists in 2 forms. | 370-497 | 370 | 497 | The primary mechanism of NSAIDs in the @OBJECT$ @PREDICAT$ @SUBJECT$ , which exists in 2 forms. |
Fact | preserve | 1521-1530 | 1521-1530 | T105 | treatment | TREATS | 1,521 | 1,530 | preserve | 1550-1559 | 1550-1559 | T93 | rofecoxib | OrganicChemical | 1,550 | 1,559 | preserve | 1534-1548 | 1534-1548 | T92 | osteoarthritis | DiseaseOrSyndrome | 1,534 | 1,548 | A15 | In the treatment of osteoarthritis, rofecoxib has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known. | 1514-1735 | 1,514 | 1,735 | In the @PREDICAT$ of @OBJECT$ , @SUBJECT$ has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known. |
Fact | preserve | 1406-1408 | 1406-1408 | T90 | in | LOCATION_OF | 1,406 | 1,408 | preserve | 1413-1418 | 1413-1418 | T84 | liver | BodyPartOrganOrOrganComponent | 1,413 | 1,418 | preserve | 1381-1390 | 1381-1390 | T83 | Celecoxib | OrganicChemical | 1,381 | 1,390 | A16 | Celecoxib is metabolized in the liver by the cytochrome P-450 isozyme CYP2C9, and thus serious drug interactions are possible. | 1381-1513 | 1,381 | 1,513 | @OBJECT$ is metabolized @PREDICAT$ the @SUBJECT$ by the cytochrome P-450 isozyme CYP2C9, and thus serious drug interactions are possible. |
Fact | preserve | 979-988 | 979-988 | T65 | treatment | TREATS | 979 | 988 | preserve | 954-960 | 954-960 | T50 | NSAIDs | PharmacologicSubstance | 954 | 960 | preserve | 992-996 | 992-996 | T53 | pain | SignOrSymptom | 992 | 996 | A17 | Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. | 814-1163 | 814 | 1,163 | Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional @SUBJECT$ in the short-term @PREDICAT$ of @OBJECT$ due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. |
Fact | preserve | 46-55 | 46-55 | T4 | treatment | TREATS | 46 | 55 | preserve | 10-37 | 27-37 | T1 | cyclooxygenase-2 inhibitors | OrganicChemical | 10 | 37 | preserve | 59-68 | 59-68 | T3 | arthritis | DiseaseOrSyndrome | 59 | 68 | A18 | Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. | 0-69 | 0 | 69 | Selective @SUBJECT$ for the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 851-896 | 887-896 | T67 | celecoxib, a highly selective COX-2 inhibitor | compared_with | 851 | 896 | preserve | 851-860 | 851-860 | T45 | celecoxib | OrganicChemical | 851 | 860 | preserve | 919-926 | 919-926 | T48 | placebo | MedicalDevice | 919 | 926 | A19 | Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. | 814-1163 | 814 | 1,163 | Preliminary data suggest that @SUBJECT$ @PREDICAT$ , is superior to @OBJECT$ and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. |
Fact | preserve | 415-424 | 415-424 | T23 | treatment | TREATS | 415 | 424 | preserve | 395-401 | 395-401 | T17 | NSAIDs | PharmacologicSubstance | 395 | 401 | preserve | 428-440 | 428-440 | T19 | inflammation | PathologicFunction | 428 | 440 | A20 | The primary mechanism of NSAIDs in the treatment of inflammation is the inhibition of COX, which exists in 2 forms. | 370-497 | 370 | 497 | The primary mechanism of @SUBJECT$ in the @PREDICAT$ of @OBJECT$ is the inhibition of COX, which exists in 2 forms. |
Fact | preserve | 1889-1902 | 1895-1902 | T120 | COX-2 therapy | ISA | 1,889 | 1,902 | preserve | 1889-1894 | 1889-1894 | T112 | COX-2 | AminoAcidPeptideOrProtein | 1,889 | 1,894 | preserve | 1895-1902 | 1895-1902 | T113 | therapy | TherapeuticOrPreventiveProcedure | 1,895 | 1,902 | A21 | Until the selective COX-2 inhibitors are widely used and more clinical as well as pharmacoeconomic studies are published, the exact role of COX-2 therapy cannot be determined. | 1736-1924 | 1,736 | 1,924 | Until the selective COX-2 inhibitors are widely used and more clinical as well as pharmacoeconomic studies are published, the exact role of @SUBJECT$ @PREDICAT$ @OBJECT$ cannot be determined. |
Fact | preserve | 640-648 | 640-648 | T39 | inhibits | INHIBITS | 640 | 648 | preserve | 629-634 | 629-634 | T30 | NSAID | PharmacologicSubstance | 629 | 634 | preserve | 649-654 | 649-654 | T31 | COX-2 | AminoAcidPeptideOrProtein | 649 | 654 | A23 | Theoretically, an NSAID that inhibits COX-2 selectively should decrease inflammation but not influence normal physiologic functions and thus should cause fewer gastrointestinal side effects. | 611-813 | 611 | 813 | Theoretically, an @SUBJECT$ that @PREDICAT$ @OBJECT$ selectively should decrease inflammation but not influence normal physiologic functions and thus should cause fewer gastrointestinal side effects. |
Fact | preserve | 1249-1258 | 1249-1258 | T81 | treatment | TREATS | 1,249 | 1,258 | preserve | 1164-1173 | 1164-1173 | T69 | Celecoxib | OrganicChemical | 1,164 | 1,173 | preserve | 1269-1289 | 1280-1289 | T73 | rheumatoid arthritis | DiseaseOrSyndrome | 1,269 | 1,289 | A24 | Celecoxib also has been shown to be as effective as traditional NSAIDs in the treatment of rheumatoid arthritis, but it may cause fewer adverse effects, including endoscopically documented ulcers. | 1164-1380 | 1,164 | 1,380 | @SUBJECT$ also has been shown to be as effective as traditional NSAIDs in the @PREDICAT$ of @OBJECT$ , but it may cause fewer adverse effects, including endoscopically documented ulcers. |
Fact | preserve | 1220-1222 | 1220-1222 | T79 | as | compared_with | 1,220 | 1,222 | preserve | 1164-1173 | 1164-1173 | T69 | Celecoxib | OrganicChemical | 1,164 | 1,173 | preserve | 1235-1241 | 1235-1241 | T71 | NSAIDs | PharmacologicSubstance | 1,235 | 1,241 | A25 | Celecoxib also has been shown to be as effective as traditional NSAIDs in the treatment of rheumatoid arthritis, but it may cause fewer adverse effects, including endoscopically documented ulcers. | 1164-1380 | 1,164 | 1,380 | @SUBJECT$ also has been shown to be as effective @PREDICAT$ traditional @OBJECT$ in the treatment of rheumatoid arthritis, but it may cause fewer adverse effects, including endoscopically documented ulcers. |
Fact | preserve | 2306-2308 | 2306-2308 | T157 | in | LOCATION_OF | 2,306 | 2,308 | preserve | 2329-2336 | 2329-2336 | T150 | animals | Animal | 2,329 | 2,336 | preserve | 2283-2287 | 2283-2287 | T148 | eNOS | AminoAcidPeptideOrProtein | 2,283 | 2,287 | A1 | CONCLUSIONS: We conclude that loss of one copy of the eNOS gene, as observed in heterozygotic animals, has no effect on vascular reactivity, blood pressure or eNOS protein expression. | 2229-2424 | 2,229 | 2,424 | CONCLUSIONS: We conclude that loss of one copy of the @OBJECT$ gene, as observed @PREDICAT$ heterozygotic @SUBJECT$ , has no effect on vascular reactivity, blood pressure or eNOS protein expression. |
Counterfact | preserve | 1200-1206 | 1200-1206 | T85 | effect | AFFECTS | 1,200 | 1,206 | preserve | 1186-1192 | 1186-1192 | T80 | L-NAME | AminoAcidPeptideOrProtein | 1,186 | 1,192 | preserve | 1210-1230 | 1222-1230 | T82 | blood pressure | Finding | 1,210 | 1,230 | A3 | In eNOS-/- mice, chronic oral administration of L-NAME had no effect on blood pressure, suggesting that inhibition of other NOS isoforms unlikely contribute to hypertension. | 1138-1323 | 1,138 | 1,323 | In eNOS-/- mice, chronic oral administration of @SUBJECT$ had no @PREDICAT$ on @OBJECT$ , suggesting that inhibition of other NOS isoforms unlikely contribute to hypertension. |
Probable | preserve | 2471-2479 | 2471-2479 | T164 | involved | AFFECTS | 2,471 | 2,479 | preserve | 2453-2457 | 2453-2457 | T160 | eNOS | AminoAcidPeptideOrProtein | 2,453 | 2,457 | preserve | 2489-2514 | 2504-2514 | T161 | blood pressure regulation | OrganismFunction | 2,489 | 2,514 | A5 | Isoforms of NOS, other than eNOS are unlikely involved in blood pressure regulation but may participate in heart rate control. | 2425-2557 | 2,425 | 2,557 | Isoforms of NOS, other than @SUBJECT$ are unlikely @PREDICAT$ in @OBJECT$ but may participate in heart rate control. |
Fact | preserve | 907-910 | 907-910 | T64 | had | PROCESS_OF | 907 | 910 | preserve | 916-928 | 916-928 | T59 | hypertension | DiseaseOrSyndrome | 916 | 928 | preserve | 902-906 | 902-906 | T57 | mice | Mammal | 902 | 906 | A9 | RESULTS: While eNOS-/- mice had mild hypertension and bradycardia, eNOS+/- mice were normotensive. | 873-983 | 873 | 983 | RESULTS: While eNOS-/- @OBJECT$ @PREDICAT$ mild @SUBJECT$ and bradycardia, eNOS+/- mice were normotensive. |
Counterfact | preserve | 117-143 | 135-143 | T13 | cell nitric oxide synthase | PART_OF | 117 | 143 | preserve | 105-143 | 135-143 | T7 | endothelial cell nitric oxide synthase | AminoAcidPeptideOrProtein | 105 | 143 | preserve | 117-121 | 117-121 | T6 | cell | Cell | 117 | 121 | A10 | Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. | 0-222 | 0 | 222 | Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the @SUBJECT$ @OBJECT$ @PREDICAT$ : contributions of NOS isoforms to blood pressure and heart rate control. |
Fact | preserve | 79-81 | 79-81 | T12 | in | PROCESS_OF | 79 | 81 | preserve | 0-18 | 8-18 | T1 | Protein expression | GeneticFunction | 0 | 18 | preserve | 88-92 | 88-92 | T5 | mice | Mammal | 88 | 92 | A13 | Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. | 0-222 | 0 | 222 | @SUBJECT$ , vascular reactivity and soluble guanylate cyclase activity @PREDICAT$ @OBJECT$ lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. |
Uncommitted | preserve | 145-158 | 145-158 | T14 | contributions | AFFECTS | 145 | 158 | preserve | 162-165 | 162-165 | T8 | NOS | AminoAcidPeptideOrProtein | 162 | 165 | preserve | 184-198 | 190-198 | T9 | blood pressure | Finding | 184 | 198 | A14 | Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. | 0-222 | 0 | 222 | Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: @PREDICAT$ of @SUBJECT$ isoforms to @OBJECT$ and heart rate control. |
Fact | preserve | 1324-1340 | 1331-1340 | T97 | L-NAME treatment | ISA | 1,324 | 1,340 | preserve | 1324-1330 | 1324-1330 | T87 | L-NAME | AminoAcidPeptideOrProtein | 1,324 | 1,330 | preserve | 1331-1340 | 1331-1340 | T88 | treatment | TherapeuticOrPreventiveProcedure | 1,331 | 1,340 | A15 | L-NAME treatment induced bradycardia in both control and eNOS-/- mice, suggesting that both eNOS and other isoforms of NOS might be involved in heart rate control. | 1324-1499 | 1,324 | 1,499 | @SUBJECT$ @PREDICAT$ @OBJECT$ induced bradycardia in both control and eNOS-/- mice, suggesting that both eNOS and other isoforms of NOS might be involved in heart rate control. |
Fact | preserve | 738-740 | 738-740 | T54 | in | PROCESS_OF | 738 | 740 | preserve | 616-634 | 624-634 | T35 | protein expression | GeneticFunction | 616 | 634 | preserve | 741-745 | 741-745 | T42 | mice | Mammal | 741 | 745 | A16 | METHODS: We examined protein expression, vascular reactivity, activity of soluble guanylate cyclase, blood pressure and heart rate in mice completely lacking the eNOS gene (eNOS-/-), wild-type mice (eNOS+/+) and mice heterozygotic for the eNOS gene (eNOS+/-). | 595-872 | 595 | 872 | METHODS: We examined @SUBJECT$ , vascular reactivity, activity of soluble guanylate cyclase, blood pressure and heart rate @PREDICAT$ @OBJECT$ completely lacking the eNOS gene (eNOS-/-), wild-type mice (eNOS+/+) and mice heterozygotic for the eNOS gene (eNOS+/-). |
Fact | preserve | 908-910 | 908-910 | T65 | in | TREATS | 908 | 910 | preserve | 744-759 | 752-759 | T54 | channel blocker | PharmacologicSubstance | 744 | 759 | preserve | 924-928 | 924-928 | T62 | rats | Mammal | 924 | 928 | A1 | Recently, another NMDA receptor-associated channel blocker, memantine, has been shown to ameliorate NMDA-receptor mediated neurotoxicity in neuronal cell cultures and in focal cerebral ischemia models in adult rats without substantial side effects. | 694-962 | 694 | 962 | Recently, another NMDA receptor-associated @SUBJECT$ , memantine, has been shown to ameliorate NMDA-receptor mediated neurotoxicity in neuronal cell cultures and in focal cerebral ischemia models @PREDICAT$ adult @OBJECT$ without substantial side effects. |
Probable | preserve | 1798-1800 | 1798-1800 | T113 | in | TREATS | 1,798 | 1,800 | preserve | 1744-1753 | 1744-1753 | T107 | memantine | OrganicChemical | 1,744 | 1,753 | preserve | 1801-1809 | 1801-1809 | T109 | neonatal | AgeGroup | 1,801 | 1,809 | A2 | Thus memantine appears to be both safe and effective in neonatal as well as adult animal models of stroke. | 1739-1858 | 1,739 | 1,858 | Thus @SUBJECT$ appears to be both safe and effective @PREDICAT$ @OBJECT$ as well as adult animal models of stroke. |
Fact | preserve | 673-675 | 673-675 | T51 | of | LOCATION_OF | 673 | 675 | preserve | 685-692 | 685-692 | T48 | neurons | Cell | 685 | 692 | preserve | 663-672 | 663-672 | T46 | apoptosis | CellFunction | 663 | 672 | A3 | However, this drug has numerous side effects and causes apoptosis of neonatal neurons. | 601-693 | 601 | 693 | However, this drug has numerous side effects and causes @OBJECT$ @PREDICAT$ neonatal @SUBJECT$ . |
Fact | preserve | 182-223 | 218-223 | T26 | glutamate or other excitatory amino acids | ASSOCIATED_WITH | 182 | 223 | preserve | 201-223 | 218-223 | T14 | excitatory amino acids | AminoAcidPeptideOrProtein | 201 | 223 | preserve | 337-354 | 346-354 | T20 | cerebral ischemia | DiseaseOrSyndrome | 337 | 354 | A5 | Excessive accumulation of glutamate or other excitatory amino acids and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury in cerebral ischemia. | 156-355 | 156 | 355 | Excessive accumulation of @PREDICAT$ @SUBJECT$ and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury in @OBJECT$ . |
Fact | preserve | 1101-1108 | 1101-1108 | T81 | effects | AFFECTS | 1,101 | 1,108 | preserve | 1112-1121 | 1112-1121 | T72 | memantine | OrganicChemical | 1,112 | 1,121 | preserve | 1131-1137 | 1131-1137 | T74 | stroke | DiseaseOrSyndrome | 1,131 | 1,137 | A6 | Here we tested the effects of memantine on focal stroke caused by photochemical thrombosis in neonatal rats and demonstrated a neuroprotective effect of memantine in this model. | 1082-1271 | 1,082 | 1,271 | Here we tested the @PREDICAT$ of @SUBJECT$ on focal @OBJECT$ caused by photochemical thrombosis in neonatal rats and demonstrated a neuroprotective effect of memantine in this model. |
Fact | preserve | 586-599 | 593-599 | T41 | stroke models | PROCESS_OF | 586 | 599 | preserve | 586-592 | 586-592 | T39 | stroke | DiseaseOrSyndrome | 586 | 592 | preserve | 579-599 | 593-599 | T40 | rodent stroke models | ExperimentalModelOfDisease | 579 | 599 | A7 | Dizocilpine (MK-801), an NMDA receptor-associated channel blocker, protects neurons in several rodent stroke models. | 472-600 | 472 | 600 | Dizocilpine (MK-801), an NMDA receptor-associated channel blocker, protects neurons in several @OBJECT$ @SUBJECT$ @PREDICAT$ . |
Probable | preserve | 304-308 | 304-308 | T23 | lead | CAUSES | 304 | 308 | preserve | 265-279 | 270-279 | T17 | NMDA receptors | AminoAcidPeptideOrProtein | 265 | 279 | preserve | 327-333 | 327-333 | T19 | injury | InjuryOrPoisoning | 327 | 333 | A8 | Excessive accumulation of glutamate or other excitatory amino acids and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury in cerebral ischemia. | 156-355 | 156 | 355 | Excessive accumulation of glutamate or other excitatory amino acids and the subsequent overactivity of @SUBJECT$ is currently thought to @PREDICAT$ to neuronal @OBJECT$ in cerebral ischemia. |
Fact | preserve | 656-662 | 656-662 | T49 | causes | CAUSES | 656 | 662 | preserve | 615-619 | 615-619 | T43 | drug | PharmacologicSubstance | 615 | 619 | preserve | 663-672 | 663-672 | T46 | apoptosis | CellFunction | 663 | 672 | A9 | However, this drug has numerous side effects and causes apoptosis of neonatal neurons. | 601-693 | 601 | 693 | However, this @SUBJECT$ has numerous side effects and @PREDICAT$ @OBJECT$ of neonatal neurons. |
Fact | preserve | 1138-1144 | 1138-1144 | T82 | caused | CAUSES | 1,138 | 1,144 | preserve | 1168-1178 | 1168-1178 | T75 | thrombosis | PathologicFunction | 1,168 | 1,178 | preserve | 1131-1137 | 1131-1137 | T74 | stroke | DiseaseOrSyndrome | 1,131 | 1,137 | A10 | Here we tested the effects of memantine on focal stroke caused by photochemical thrombosis in neonatal rats and demonstrated a neuroprotective effect of memantine in this model. | 1082-1271 | 1,082 | 1,271 | Here we tested the effects of memantine on focal @OBJECT$ @PREDICAT$ by photochemical @SUBJECT$ in neonatal rats and demonstrated a neuroprotective effect of memantine in this model. |
Fact | preserve | 182-223 | 218-223 | T26 | glutamate or other excitatory amino acids | ASSOCIATED_WITH | 182 | 223 | preserve | 182-191 | 182-191 | T13 | glutamate | AminoAcidPeptideOrProtein | 182 | 191 | preserve | 337-354 | 346-354 | T20 | cerebral ischemia | DiseaseOrSyndrome | 337 | 354 | A11 | Excessive accumulation of glutamate or other excitatory amino acids and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury in cerebral ischemia. | 156-355 | 156 | 355 | Excessive accumulation of @SUBJECT$ @PREDICAT$ and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury in @OBJECT$ . |
Fact | preserve | 334-336 | 334-336 | T24 | in | ASSOCIATED_WITH | 334 | 336 | preserve | 182-191 | 182-191 | T13 | glutamate | AminoAcidPeptideOrProtein | 182 | 191 | preserve | 337-354 | 346-354 | T20 | cerebral ischemia | DiseaseOrSyndrome | 337 | 354 | A12 | Excessive accumulation of glutamate or other excitatory amino acids and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury in cerebral ischemia. | 156-355 | 156 | 355 | Excessive accumulation of @SUBJECT$ or other excitatory amino acids and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury @PREDICAT$ @OBJECT$ . |
Fact | preserve | 182-223 | 218-223 | T21 | glutamate or other excitatory amino acids | ISA | 182 | 223 | preserve | 182-191 | 182-191 | T13 | glutamate | AminoAcidPeptideOrProtein | 182 | 191 | preserve | 201-223 | 218-223 | T14 | excitatory amino acids | AminoAcidPeptideOrProtein | 201 | 223 | A13 | Excessive accumulation of glutamate or other excitatory amino acids and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury in cerebral ischemia. | 156-355 | 156 | 355 | Excessive accumulation of @SUBJECT$ @PREDICAT$ @OBJECT$ and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury in cerebral ischemia. |
Fact | preserve | 676-692 | 685-692 | T50 | neonatal neurons | PART_OF | 676 | 692 | preserve | 685-692 | 685-692 | T48 | neurons | Cell | 685 | 692 | preserve | 676-684 | 676-684 | T47 | neonatal | AgeGroup | 676 | 684 | A15 | However, this drug has numerous side effects and causes apoptosis of neonatal neurons. | 601-693 | 601 | 693 | However, this drug has numerous side effects and causes apoptosis of @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 139-141 | 139-141 | T11 | in | PROCESS_OF | 139 | 141 | preserve | 115-138 | 130-138 | T8 | cerebral focal ischemia | DiseaseOrSyndrome | 115 | 138 | preserve | 151-154 | 151-154 | T10 | rat | Mammal | 151 | 154 | A16 | Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. | 0-155 | 0 | 155 | Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of @SUBJECT$ @PREDICAT$ neonatal @OBJECT$ . |
Fact | preserve | 334-336 | 334-336 | T24 | in | ASSOCIATED_WITH | 334 | 336 | preserve | 201-223 | 218-223 | T14 | excitatory amino acids | AminoAcidPeptideOrProtein | 201 | 223 | preserve | 337-354 | 346-354 | T20 | cerebral ischemia | DiseaseOrSyndrome | 337 | 354 | A20 | Excessive accumulation of glutamate or other excitatory amino acids and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury in cerebral ischemia. | 156-355 | 156 | 355 | Excessive accumulation of glutamate or other @SUBJECT$ and the subsequent overactivity of NMDA receptors is currently thought to lead to neuronal injury @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1179-1181 | 1179-1181 | T83 | in | PROCESS_OF | 1,179 | 1,181 | preserve | 1168-1178 | 1168-1178 | T75 | thrombosis | PathologicFunction | 1,168 | 1,178 | preserve | 1191-1195 | 1191-1195 | T77 | rats | Mammal | 1,191 | 1,195 | A21 | Here we tested the effects of memantine on focal stroke caused by photochemical thrombosis in neonatal rats and demonstrated a neuroprotective effect of memantine in this model. | 1082-1271 | 1,082 | 1,271 | Here we tested the effects of memantine on focal stroke caused by photochemical @SUBJECT$ @PREDICAT$ neonatal @OBJECT$ and demonstrated a neuroprotective effect of memantine in this model. |
Fact | preserve | 1011-1020 | 1011-1020 | T70 | treatment | TREATS | 1,011 | 1,020 | preserve | 963-972 | 963-972 | T66 | Memantine | OrganicChemical | 963 | 972 | preserve | 1024-1043 | 1036-1043 | T68 | Parkinson's disease | DiseaseOrSyndrome | 1,024 | 1,043 | A22 | Memantine has been used clinically in the treatment of Parkinson's disease and spasticity for a number of years. | 963-1081 | 963 | 1,081 | @SUBJECT$ has been used clinically in the @PREDICAT$ of @OBJECT$ and spasticity for a number of years. |
Fact | preserve | 976-978 | 976-978 | T69 | in | PROCESS_OF | 976 | 978 | preserve | 972-975 | 972-975 | T59 | SCD | PathologicFunction | 972 | 975 | preserve | 985-993 | 985-993 | T60 | patients | PatientOrDisabledGroup | 985 | 993 | A1 | Primary prevention of SCD in patients with a recent myocardial infarction (MI) and in patients with cardiomyopathy and congestive heart failure (CHF) is limited by our inability to accurately identify patients at risk of SCD. | 950-1194 | 950 | 1,194 | Primary prevention of @SUBJECT$ @PREDICAT$ @OBJECT$ with a recent myocardial infarction (MI) and in patients with cardiomyopathy and congestive heart failure (CHF) is limited by our inability to accurately identify patients at risk of SCD. |
Fact | preserve | 1518-1522 | 1518-1522 | T92 | with | PROCESS_OF | 1,518 | 1,522 | preserve | 1523-1537 | 1523-1537 | T88 | cardiomyopathy | DiseaseOrSyndrome | 1,523 | 1,537 | preserve | 1509-1517 | 1509-1517 | T87 | patients | PatientOrDisabledGroup | 1,509 | 1,517 | A2 | To date, only beta adrenoceptor blockers have been shown to improve survival in post-MI patients as well as in patients with cardiomyopathy and CHF. | 1386-1546 | 1,386 | 1,546 | To date, only beta adrenoceptor blockers have been shown to improve survival in post-MI patients as well as in @OBJECT$ @PREDICAT$ @SUBJECT$ and CHF. |
Fact | preserve | 1469-1471 | 1469-1471 | T91 | in | TREATS | 1,469 | 1,471 | preserve | 1406-1432 | 1424-1432 | T82 | beta adrenoceptor blockers | PharmacologicSubstance | 1,406 | 1,432 | preserve | 1486-1494 | 1486-1494 | T86 | patients | PatientOrDisabledGroup | 1,486 | 1,494 | A4 | To date, only beta adrenoceptor blockers have been shown to improve survival in post-MI patients as well as in patients with cardiomyopathy and CHF. | 1386-1546 | 1,386 | 1,546 | To date, only @SUBJECT$ have been shown to improve survival @PREDICAT$ post-MI @OBJECT$ as well as in patients with cardiomyopathy and CHF. |
Fact | preserve | 794-803 | 794-803 | T46 | treatment | TREATS | 794 | 803 | preserve | 759-766 | 759-766 | T33 | sotalol | OrganicChemical | 759 | 766 | preserve | 820-822 | 820-822 | T37 | VF | DiseaseOrSyndrome | 820 | 822 | A5 | Amiodarone and sotalol, though very useful in the treatment of VT and VF, do not improve survival as significantly as ICD therapy. | 744-880 | 744 | 880 | Amiodarone and @SUBJECT$ , though very useful in the @PREDICAT$ of VT and @OBJECT$ , do not improve survival as significantly as ICD therapy. |
Fact | preserve | 1469-1471 | 1469-1471 | T91 | in | TREATS | 1,469 | 1,471 | preserve | 1406-1432 | 1424-1432 | T82 | beta adrenoceptor blockers | PharmacologicSubstance | 1,406 | 1,432 | preserve | 1477-1479 | 1477-1479 | T85 | MI | DiseaseOrSyndrome | 1,477 | 1,479 | A6 | To date, only beta adrenoceptor blockers have been shown to improve survival in post-MI patients as well as in patients with cardiomyopathy and CHF. | 1386-1546 | 1,386 | 1,546 | To date, only @SUBJECT$ have been shown to improve survival @PREDICAT$ post- @OBJECT$ patients as well as in patients with cardiomyopathy and CHF. |
Fact | preserve | 794-803 | 794-803 | T46 | treatment | TREATS | 794 | 803 | preserve | 744-754 | 744-754 | T32 | Amiodarone | OrganicChemical | 744 | 754 | preserve | 813-815 | 813-815 | T36 | VT | PathologicFunction | 813 | 815 | A7 | Amiodarone and sotalol, though very useful in the treatment of VT and VF, do not improve survival as significantly as ICD therapy. | 744-880 | 744 | 880 | @SUBJECT$ and sotalol, though very useful in the @PREDICAT$ of @OBJECT$ and VF, do not improve survival as significantly as ICD therapy. |
Fact | preserve | 994-998 | 994-998 | T71 | with | PROCESS_OF | 994 | 998 | preserve | 1008-1029 | 1019-1029 | T62 | myocardial infarction | DiseaseOrSyndrome | 1,008 | 1,029 | preserve | 985-993 | 985-993 | T60 | patients | PatientOrDisabledGroup | 985 | 993 | A8 | Primary prevention of SCD in patients with a recent myocardial infarction (MI) and in patients with cardiomyopathy and congestive heart failure (CHF) is limited by our inability to accurately identify patients at risk of SCD. | 950-1194 | 950 | 1,194 | Primary prevention of SCD in @OBJECT$ @PREDICAT$ a recent @SUBJECT$ (MI) and in patients with cardiomyopathy and congestive heart failure (CHF) is limited by our inability to accurately identify patients at risk of SCD. |
Fact | preserve | 868-879 | 872-879 | T50 | ICD therapy | USES | 868 | 879 | preserve | 872-879 | 872-879 | T41 | therapy | TherapeuticOrPreventiveProcedure | 872 | 879 | preserve | 868-871 | 868-871 | T40 | ICD | MedicalDevice | 868 | 871 | A9 | Amiodarone and sotalol, though very useful in the treatment of VT and VF, do not improve survival as significantly as ICD therapy. | 744-880 | 744 | 880 | Amiodarone and sotalol, though very useful in the treatment of VT and VF, do not improve survival as significantly as @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 794-803 | 794-803 | T46 | treatment | TREATS | 794 | 803 | preserve | 759-766 | 759-766 | T33 | sotalol | OrganicChemical | 759 | 766 | preserve | 813-815 | 813-815 | T36 | VT | PathologicFunction | 813 | 815 | A12 | Amiodarone and sotalol, though very useful in the treatment of VT and VF, do not improve survival as significantly as ICD therapy. | 744-880 | 744 | 880 | Amiodarone and @SUBJECT$ , though very useful in the @PREDICAT$ of @OBJECT$ and VF, do not improve survival as significantly as ICD therapy. |
Fact | preserve | 868-879 | 872-879 | T45 | ICD therapy | ISA | 868 | 879 | preserve | 868-871 | 868-871 | T40 | ICD | MedicalDevice | 868 | 871 | preserve | 872-879 | 872-879 | T41 | therapy | TherapeuticOrPreventiveProcedure | 872 | 879 | A13 | Amiodarone and sotalol, though very useful in the treatment of VT and VF, do not improve survival as significantly as ICD therapy. | 744-880 | 744 | 880 | Amiodarone and sotalol, though very useful in the treatment of VT and VF, do not improve survival as significantly as @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1607-1616 | 1607-1616 | T110 | Treatment | TREATS | 1,607 | 1,616 | preserve | 1622-1625 | 1622-1625 | T101 | ICD | MedicalDevice | 1,622 | 1,625 | preserve | 1634-1636 | 1634-1636 | T103 | MI | DiseaseOrSyndrome | 1,634 | 1,636 | A14 | Treatment with ICD of post-MI patients with decreased LVEF and inducible sustained VT at electrophysiology study improves survival. | 1607-1750 | 1,607 | 1,750 | @PREDICAT$ with @SUBJECT$ of post- @OBJECT$ patients with decreased LVEF and inducible sustained VT at electrophysiology study improves survival. |
Fact | preserve | 581-585 | 581-585 | T30 | with | PROCESS_OF | 581 | 585 | preserve | 586-598 | 596-598 | T25 | sustained VT | DiseaseOrSyndrome | 586 | 598 | preserve | 572-580 | 572-580 | T24 | patients | PatientOrDisabledGroup | 572 | 580 | A15 | In patients with sustained VT and aborted SCD, only treatment with implantable cardioverter defibrillator (ICD) has been shown to significantly increase survival. | 569-743 | 569 | 743 | In @OBJECT$ @PREDICAT$ @SUBJECT$ and aborted SCD, only treatment with implantable cardioverter defibrillator (ICD) has been shown to significantly increase survival. |
Fact | preserve | 1518-1522 | 1518-1522 | T92 | with | PROCESS_OF | 1,518 | 1,522 | preserve | 1542-1545 | 1542-1545 | T89 | CHF | DiseaseOrSyndrome | 1,542 | 1,545 | preserve | 1509-1517 | 1509-1517 | T87 | patients | PatientOrDisabledGroup | 1,509 | 1,517 | A16 | To date, only beta adrenoceptor blockers have been shown to improve survival in post-MI patients as well as in patients with cardiomyopathy and CHF. | 1386-1546 | 1,386 | 1,546 | To date, only beta adrenoceptor blockers have been shown to improve survival in post-MI patients as well as in @OBJECT$ @PREDICAT$ cardiomyopathy and @SUBJECT$ . |
Fact | preserve | 1477-1494 | 1486-1494 | T90 | MI patients | PROCESS_OF | 1,477 | 1,494 | preserve | 1477-1479 | 1477-1479 | T85 | MI | DiseaseOrSyndrome | 1,477 | 1,479 | preserve | 1486-1494 | 1486-1494 | T86 | patients | PatientOrDisabledGroup | 1,486 | 1,494 | A17 | To date, only beta adrenoceptor blockers have been shown to improve survival in post-MI patients as well as in patients with cardiomyopathy and CHF. | 1386-1546 | 1,386 | 1,546 | To date, only beta adrenoceptor blockers have been shown to improve survival in post- @SUBJECT$ @PREDICAT$ @OBJECT$ as well as in patients with cardiomyopathy and CHF. |
Fact | preserve | 533-537 | 533-537 | T23 | with | PROCESS_OF | 533 | 537 | preserve | 538-567 | 556-567 | T22 | ventricular arrhythmias | PathologicFunction | 538 | 567 | preserve | 524-532 | 524-532 | T21 | patients | PatientOrDisabledGroup | 524 | 532 | A20 | Several major arrhythmia treatment trials completed during the last decade have significantly changed the way we treat patients with ventricular arrhythmias. | 398-568 | 398 | 568 | Several major arrhythmia treatment trials completed during the last decade have significantly changed the way we treat @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1634-1645 | 1637-1645 | T111 | MI patients | PROCESS_OF | 1,634 | 1,645 | preserve | 1634-1636 | 1634-1636 | T103 | MI | DiseaseOrSyndrome | 1,634 | 1,636 | preserve | 1637-1645 | 1637-1645 | T104 | patients | PatientOrDisabledGroup | 1,637 | 1,645 | A21 | Treatment with ICD of post-MI patients with decreased LVEF and inducible sustained VT at electrophysiology study improves survival. | 1607-1750 | 1,607 | 1,750 | Treatment with ICD of post- @SUBJECT$ @PREDICAT$ @OBJECT$ with decreased LVEF and inducible sustained VT at electrophysiology study improves survival. |
Fact | preserve | 631-635 | 631-635 | T31 | with | USES | 631 | 635 | preserve | 621-630 | 621-630 | T27 | treatment | TherapeuticOrPreventiveProcedure | 621 | 630 | preserve | 642-680 | 667-680 | T28 | implantable cardioverter defibrillator | MedicalDevice | 642 | 680 | A22 | In patients with sustained VT and aborted SCD, only treatment with implantable cardioverter defibrillator (ICD) has been shown to significantly increase survival. | 569-743 | 569 | 743 | In patients with sustained VT and aborted SCD, only @SUBJECT$ @PREDICAT$ @OBJECT$ (ICD) has been shown to significantly increase survival. |
Fact | preserve | 1588-1590 | 1588-1590 | T99 | in | TREATS | 1,588 | 1,590 | preserve | 1554-1564 | 1554-1564 | T96 | amiodarone | OrganicChemical | 1,554 | 1,564 | preserve | 1597-1605 | 1597-1605 | T98 | patients | PatientOrDisabledGroup | 1,597 | 1,605 | A23 | Use of amiodarone is controversial in these patients. | 1547-1606 | 1,547 | 1,606 | Use of @SUBJECT$ is controversial @PREDICAT$ these @OBJECT$ . |
Fact | preserve | 1607-1616 | 1607-1616 | T110 | Treatment | TREATS | 1,607 | 1,616 | preserve | 1622-1625 | 1622-1625 | T101 | ICD | MedicalDevice | 1,622 | 1,625 | preserve | 1637-1645 | 1637-1645 | T104 | patients | PatientOrDisabledGroup | 1,637 | 1,645 | A24 | Treatment with ICD of post-MI patients with decreased LVEF and inducible sustained VT at electrophysiology study improves survival. | 1607-1750 | 1,607 | 1,750 | @PREDICAT$ with @SUBJECT$ of post-MI @OBJECT$ with decreased LVEF and inducible sustained VT at electrophysiology study improves survival. |
Fact | preserve | 794-803 | 794-803 | T46 | treatment | TREATS | 794 | 803 | preserve | 744-754 | 744-754 | T32 | Amiodarone | OrganicChemical | 744 | 754 | preserve | 820-822 | 820-822 | T37 | VF | DiseaseOrSyndrome | 820 | 822 | A25 | Amiodarone and sotalol, though very useful in the treatment of VT and VF, do not improve survival as significantly as ICD therapy. | 744-880 | 744 | 880 | @SUBJECT$ and sotalol, though very useful in the @PREDICAT$ of VT and @OBJECT$ , do not improve survival as significantly as ICD therapy. |
Probable | preserve | 1331-1339 | 1331-1339 | T80 | presence | COEXISTS_WITH | 1,331 | 1,339 | preserve | 1264-1267 | 1264-1267 | T77 | SCD | PathologicFunction | 1,264 | 1,267 | preserve | 1343-1359 | 1357-1359 | T79 | non-sustained VT | DiseaseOrSyndrome | 1,343 | 1,359 | A27 | Among the many tests available to identify patients at risk of SCD, decreased left ventricular ejection fraction (LVEF) and presence of non-sustained VT appear to be most useful. | 1195-1385 | 1,195 | 1,385 | Among the many tests available to identify patients at risk of @SUBJECT$ , decreased left ventricular ejection fraction (LVEF) and @PREDICAT$ of @OBJECT$ appear to be most useful. |
Fact | preserve | 976-978 | 976-978 | T69 | in | PROCESS_OF | 976 | 978 | preserve | 972-975 | 972-975 | T59 | SCD | PathologicFunction | 972 | 975 | preserve | 1042-1050 | 1042-1050 | T63 | patients | PatientOrDisabledGroup | 1,042 | 1,050 | A28 | Primary prevention of SCD in patients with a recent myocardial infarction (MI) and in patients with cardiomyopathy and congestive heart failure (CHF) is limited by our inability to accurately identify patients at risk of SCD. | 950-1194 | 950 | 1,194 | Primary prevention of @SUBJECT$ @PREDICAT$ patients with a recent myocardial infarction (MI) and in @OBJECT$ with cardiomyopathy and congestive heart failure (CHF) is limited by our inability to accurately identify patients at risk of SCD. |
Fact | preserve | 900-908 | 900-908 | T55 | revealed | DIAGNOSES | 900 | 908 | preserve | 876-879 | 876-879 | T52 | MRI | DiagnosticProcedure | 876 | 879 | preserve | 923-936 | 931-936 | T54 | adrenal tumor | NeoplasticProcess | 923 | 936 | A1 | Nevertheless, the response to glucocorticoid was incomplete and an MRI was obtained, which revealed a right adrenal tumor. | 803-937 | 803 | 937 | Nevertheless, the response to glucocorticoid was incomplete and an @SUBJECT$ was obtained, which @PREDICAT$ a right @OBJECT$ . |
Fact | preserve | 251-255 | 251-255 | T21 | with | PROCESS_OF | 251 | 255 | preserve | 284-296 | 284-296 | T18 | hypertension | DiseaseOrSyndrome | 284 | 296 | preserve | 246-250 | 246-250 | T16 | girl | PopulationGroup | 246 | 250 | A2 | We describe a rare androgen and desoxycorticosterone (DOC)-secreting adrenal tumor in a non-Cushingoid 14 year-old Haitian girl with secondary amenorrhea, hypertension and virilization. | 117-314 | 117 | 314 | We describe a rare androgen and desoxycorticosterone (DOC)-secreting adrenal tumor in a non-Cushingoid 14 year-old Haitian @OBJECT$ @PREDICAT$ secondary amenorrhea, @SUBJECT$ and virilization. |
Fact | preserve | 251-255 | 251-255 | T21 | with | PROCESS_OF | 251 | 255 | preserve | 301-313 | 301-313 | T19 | virilization | SignOrSymptom | 301 | 313 | preserve | 246-250 | 246-250 | T16 | girl | PopulationGroup | 246 | 250 | A6 | We describe a rare androgen and desoxycorticosterone (DOC)-secreting adrenal tumor in a non-Cushingoid 14 year-old Haitian girl with secondary amenorrhea, hypertension and virilization. | 117-314 | 117 | 314 | We describe a rare androgen and desoxycorticosterone (DOC)-secreting adrenal tumor in a non-Cushingoid 14 year-old Haitian @OBJECT$ @PREDICAT$ secondary amenorrhea, hypertension and @SUBJECT$ . |
Fact | preserve | 251-255 | 251-255 | T21 | with | PROCESS_OF | 251 | 255 | preserve | 256-276 | 266-276 | T17 | secondary amenorrhea | DiseaseOrSyndrome | 256 | 276 | preserve | 246-250 | 246-250 | T16 | girl | PopulationGroup | 246 | 250 | A7 | We describe a rare androgen and desoxycorticosterone (DOC)-secreting adrenal tumor in a non-Cushingoid 14 year-old Haitian girl with secondary amenorrhea, hypertension and virilization. | 117-314 | 117 | 314 | We describe a rare androgen and desoxycorticosterone (DOC)-secreting adrenal tumor in a non-Cushingoid 14 year-old Haitian @OBJECT$ @PREDICAT$ @SUBJECT$ , hypertension and virilization. |
Fact | preserve | 719-726 | 719-726 | T47 | reduced | INHIBITS | 719 | 726 | preserve | 620-633 | 620-633 | T41 | Dexamethasone | PharmacologicSubstance | 620 | 633 | preserve | 727-730 | 727-730 | T45 | DOC | Hormone | 727 | 730 | A9 | Dexamethasone (DEX) was administered, therefore, which partially suppressed androgen levels, reduced DOC and S by 80% and 82% respectively, and normalized blood pressure. | 620-802 | 620 | 802 | @SUBJECT$ (DEX) was administered, therefore, which partially suppressed androgen levels, @PREDICAT$ @OBJECT$ and S by 80% and 82% respectively, and normalized blood pressure. |
Fact | preserve | 1313-1323 | 1313-1323 | T77 | inhibition | INHIBITS | 1,313 | 1,323 | preserve | 1372-1381 | 1372-1381 | T76 | androgens | Hormone | 1,372 | 1,381 | preserve | 1327-1352 | 1336-1352 | T73 | 11 beta-hydroxylase | AminoAcidPeptideOrProtein | 1,327 | 1,352 | A11 | This case also allows speculation that the hypersecretion of DOC may result from inhibition of 11 beta-hydroxylase activity by excess androgens. | 1226-1382 | 1,226 | 1,382 | This case also allows speculation that the hypersecretion of DOC may result from @PREDICAT$ of @OBJECT$ activity by excess @SUBJECT$ . |
Fact | preserve | 524-534 | 524-534 | T38 | stimulated | AUGMENTS | 524 | 534 | preserve | 519-523 | 519-523 | T36 | ACTH | AminoAcidPeptideOrProtein | 519 | 523 | preserve | 535-550 | 535-550 | T37 | steroidogenesis | MolecularFunction | 535 | 550 | A13 | Exogenous ACTH stimulated steroidogenesis. | 509-551 | 509 | 551 | Exogenous @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 206-208 | 206-208 | T20 | in | PROCESS_OF | 206 | 208 | preserve | 186-205 | 200-205 | T13 | adrenal tumor | NeoplasticProcess | 186 | 205 | preserve | 246-250 | 246-250 | T16 | girl | PopulationGroup | 246 | 250 | A14 | We describe a rare androgen and desoxycorticosterone (DOC)-secreting adrenal tumor in a non-Cushingoid 14 year-old Haitian girl with secondary amenorrhea, hypertension and virilization. | 117-314 | 117 | 314 | We describe a rare androgen and desoxycorticosterone (DOC)-secreting @SUBJECT$ @PREDICAT$ a non-Cushingoid 14 year-old Haitian @OBJECT$ with secondary amenorrhea, hypertension and virilization. |
Fact | preserve | 1935-1937 | 1935-1937 | T120 | in | PROCESS_OF | 1,935 | 1,937 | preserve | 1908-1921 | 1915-1921 | T116 | breast cancer | NeoplasticProcess | 1,908 | 1,921 | preserve | 1949-1957 | 1949-1957 | T118 | patients | PatientOrDisabledGroup | 1,949 | 1,957 | A2 | Traditional risk factors for breast cancer were similar in case-patients and controls. | 1879-1971 | 1,879 | 1,971 | Traditional risk factors for @SUBJECT$ were similar @PREDICAT$ case- @OBJECT$ and controls. |
Fact | preserve | 2436-2458 | 2449-2458 | T158 | antiestrogen treatment | METHOD_OF | 2,436 | 2,458 | preserve | 2436-2448 | 2436-2448 | T149 | antiestrogen | PharmacologicSubstance | 2,436 | 2,448 | preserve | 2469-2487 | 2477-2487 | T151 | primary prevention | TherapeuticOrPreventiveProcedure | 2,469 | 2,487 | A3 | Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen treatment for primary prevention. | 2317-2488 | 2,317 | 2,488 | Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from @SUBJECT$ @PREDICAT$ for @OBJECT$ . |
Fact | preserve | 1418-1422 | 1418-1422 | T95 | risk | PREDISPOSES | 1,418 | 1,422 | preserve | 1490-1507 | 1495-1507 | T92 | free testosterone | Hormone | 1,490 | 1,507 | preserve | 1427-1446 | 1440-1446 | T89 | breast cancer | NeoplasticProcess | 1,427 | 1,446 | A8 | The risk for breast cancer in women with the highest concentration of free testosterone compared with those with the lowest concentration was 3.3 (CI, 1.1 to 10.3). | 1414-1590 | 1,414 | 1,590 | The @PREDICAT$ for @OBJECT$ in women with the highest concentration of @SUBJECT$ compared with those with the lowest concentration was 3.3 (CI, 1.1 to 10.3). |
Possible | preserve | 2423-2430 | 2423-2430 | T153 | benefit | TREATS | 2,423 | 2,430 | preserve | 2449-2458 | 2449-2458 | T150 | treatment | TherapeuticOrPreventiveProcedure | 2,449 | 2,458 | preserve | 2360-2373 | 2367-2373 | T146 | breast cancer | NeoplasticProcess | 2,360 | 2,373 | A9 | Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen treatment for primary prevention. | 2317-2488 | 2,317 | 2,488 | Women identified as being at high risk for @OBJECT$ as determined by these hormone levels may @PREDICAT$ from antiestrogen @SUBJECT$ for primary prevention. |
Fact | preserve | 1447-1449 | 1447-1449 | T96 | in | PROCESS_OF | 1,447 | 1,449 | preserve | 1427-1446 | 1440-1446 | T89 | breast cancer | NeoplasticProcess | 1,427 | 1,446 | preserve | 1450-1455 | 1450-1455 | T90 | women | PopulationGroup | 1,450 | 1,455 | A10 | The risk for breast cancer in women with the highest concentration of free testosterone compared with those with the lowest concentration was 3.3 (CI, 1.1 to 10.3). | 1414-1590 | 1,414 | 1,590 | The risk for @SUBJECT$ @PREDICAT$ @OBJECT$ with the highest concentration of free testosterone compared with those with the lowest concentration was 3.3 (CI, 1.1 to 10.3). |
Fact | preserve | 2436-2458 | 2449-2458 | T154 | antiestrogen treatment | USES | 2,436 | 2,458 | preserve | 2449-2458 | 2449-2458 | T150 | treatment | TherapeuticOrPreventiveProcedure | 2,449 | 2,458 | preserve | 2436-2448 | 2436-2448 | T149 | antiestrogen | PharmacologicSubstance | 2,436 | 2,448 | A14 | Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen treatment for primary prevention. | 2317-2488 | 2,317 | 2,488 | Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from @OBJECT$ @PREDICAT$ @SUBJECT$ for primary prevention. |
Fact | preserve | 1220-1222 | 1220-1222 | T87 | in | PROCESS_OF | 1,220 | 1,222 | preserve | 1206-1219 | 1213-1219 | T78 | breast cancer | NeoplasticProcess | 1,206 | 1,219 | preserve | 1223-1228 | 1223-1228 | T79 | women | PopulationGroup | 1,223 | 1,228 | A15 | RESULTS: The relative risk for breast cancer in women with the highest concentration of bioavailable estradiol (> or = 6.83 pmol/L or 1.9 pg/mL) was 3.6 (95% CI, 1.3 to 10.0) compared with women with the lowest concentration. | 1169-1413 | 1,169 | 1,413 | RESULTS: The relative risk for @SUBJECT$ @PREDICAT$ @OBJECT$ with the highest concentration of bioavailable estradiol (> or = 6.83 pmol/L or 1.9 pg/mL) was 3.6 (95% CI, 1.3 to 10.0) compared with women with the lowest concentration. |
Counterfact | preserve | 806-815 | 806-815 | T59 | receiving | ADMINISTERED_TO | 806 | 815 | preserve | 816-824 | 816-824 | T57 | estrogen | Hormone | 816 | 824 | preserve | 742-747 | 742-747 | T51 | women | PopulationGroup | 742 | 747 | A16 | PARTICIPANTS: 97 women with confirmed incident breast cancer and 244 randomly selected controls; all women were white, 65 years of age or older, and were not receiving estrogen. | 635-825 | 635 | 825 | PARTICIPANTS: 97 women with confirmed incident breast cancer and 244 randomly selected controls; all @OBJECT$ were white, 65 years of age or older, and were not @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1685-1687 | 1685-1687 | T113 | in | PROCESS_OF | 1,685 | 1,687 | preserve | 1624-1637 | 1631-1637 | T99 | breast cancer | NeoplasticProcess | 1,624 | 1,637 | preserve | 1694-1699 | 1694-1699 | T102 | women | PopulationGroup | 1,694 | 1,699 | A17 | The estimated incidence of breast cancer per 1000 person-years was 0.4 (CI, 0.0 to 1.3) in women with the lowest levels of bioavailable estradiol and free testosterone compared with 6.5 (CI, 2.7 to 10.3) in women with the highest concentrations of these hormones. | 1591-1878 | 1,591 | 1,878 | The estimated incidence of @SUBJECT$ per 1000 person-years was 0.4 (CI, 0.0 to 1.3) @PREDICAT$ @OBJECT$ with the lowest levels of bioavailable estradiol and free testosterone compared with 6.5 (CI, 2.7 to 10.3) in women with the highest concentrations of these hormones. |
Fact | preserve | 658-662 | 658-662 | T58 | with | PROCESS_OF | 658 | 662 | preserve | 688-701 | 695-701 | T48 | breast cancer | NeoplasticProcess | 688 | 701 | preserve | 652-657 | 652-657 | T45 | women | PopulationGroup | 652 | 657 | A19 | PARTICIPANTS: 97 women with confirmed incident breast cancer and 244 randomly selected controls; all women were white, 65 years of age or older, and were not receiving estrogen. | 635-825 | 635 | 825 | PARTICIPANTS: 97 @OBJECT$ @PREDICAT$ confirmed incident @SUBJECT$ and 244 randomly selected controls; all women were white, 65 years of age or older, and were not receiving estrogen. |
Fact | preserve | 2459-2462 | 2459-2462 | T155 | for | METHOD_OF | 2,459 | 2,462 | preserve | 2449-2458 | 2449-2458 | T150 | treatment | TherapeuticOrPreventiveProcedure | 2,449 | 2,458 | preserve | 2469-2487 | 2477-2487 | T151 | primary prevention | TherapeuticOrPreventiveProcedure | 2,469 | 2,487 | A20 | Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen treatment for primary prevention. | 2317-2488 | 2,317 | 2,488 | Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 2436-2458 | 2449-2458 | T152 | antiestrogen treatment | ISA | 2,436 | 2,458 | preserve | 2436-2448 | 2436-2448 | T149 | antiestrogen | PharmacologicSubstance | 2,436 | 2,448 | preserve | 2449-2458 | 2449-2458 | T150 | treatment | TherapeuticOrPreventiveProcedure | 2,449 | 2,458 | A21 | Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen treatment for primary prevention. | 2317-2488 | 2,317 | 2,488 | Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from @SUBJECT$ @PREDICAT$ @OBJECT$ for primary prevention. |
Fact | preserve | 2436-2458 | 2449-2458 | T156 | antiestrogen treatment | TREATS | 2,436 | 2,458 | preserve | 2436-2448 | 2436-2448 | T149 | antiestrogen | PharmacologicSubstance | 2,436 | 2,448 | preserve | 2360-2373 | 2367-2373 | T146 | breast cancer | NeoplasticProcess | 2,360 | 2,373 | A22 | Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen treatment for primary prevention. | 2317-2488 | 2,317 | 2,488 | Women identified as being at high risk for @OBJECT$ as determined by these hormone levels may benefit from @SUBJECT$ @PREDICAT$ for primary prevention. |
Fact | preserve | 1373-1390 | 1382-1390 | T87 | diabetic patients | PROCESS_OF | 1,373 | 1,390 | preserve | 1373-1381 | 1373-1381 | T85 | diabetic | Finding | 1,373 | 1,381 | preserve | 1382-1390 | 1382-1390 | T86 | patients | PatientOrDisabledGroup | 1,382 | 1,390 | A1 | However, a twofold increase of lactate and pyruvate levels was measured in obese diabetic patients. | 1286-1391 | 1,286 | 1,391 | However, a twofold increase of lactate and pyruvate levels was measured in obese @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1640-1657 | 1649-1657 | T106 | diabetic patients | PROCESS_OF | 1,640 | 1,657 | preserve | 1640-1648 | 1640-1648 | T104 | diabetic | Finding | 1,640 | 1,648 | preserve | 1649-1657 | 1649-1657 | T105 | patients | PatientOrDisabledGroup | 1,649 | 1,657 | A4 | Higher SI and lower fasting glucose were measured in lean diabetic patients only (P < 0.05). | 1576-1674 | 1,576 | 1,674 | Higher SI and lower fasting glucose were measured in lean @SUBJECT$ @PREDICAT$ @OBJECT$ only (P < 0.05). |
Fact | preserve | 831-854 | 846-854 | T59 | diabetic patients | PROCESS_OF | 831 | 854 | preserve | 831-839 | 831-839 | T51 | diabetic | Finding | 831 | 839 | preserve | 846-854 | 846-854 | T52 | patients | PatientOrDisabledGroup | 846 | 854 | A5 | Serum lactate and pyruvate levels of diabetic patients after glucose loading were compared with those of lean (n = 10) and obese (n = 10) healthy control subjects in which SI and SG were also determined from FSIGTT data. | 794-1032 | 794 | 1,032 | Serum lactate and pyruvate levels of @SUBJECT$ @PREDICAT$ @OBJECT$ after glucose loading were compared with those of lean (n = 10) and obese (n = 10) healthy control subjects in which SI and SG were also determined from FSIGTT data. |
Fact | preserve | 1812-1824 | 1815-1824 | T119 | LA treatment | ISA | 1,812 | 1,824 | preserve | 1812-1814 | 1812-1814 | T117 | LA | OrganicChemical | 1,812 | 1,814 | preserve | 1815-1824 | 1815-1824 | T118 | treatment | TherapeuticOrPreventiveProcedure | 1,815 | 1,824 | A6 | Lactate and pyruvate before and after glucose loading were approximately 45% lower in lean and obese diabetic patients after LA treatment. | 1675-1825 | 1,675 | 1,825 | Lactate and pyruvate before and after glucose loading were approximately 45% lower in lean and obese diabetic patients after @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1125-1129 | 1125-1129 | T68 | with | PROCESS_OF | 1,125 | 1,129 | preserve | 1130-1145 | 1137-1145 | T66 | type 2 diabetes | DiseaseOrSyndrome | 1,130 | 1,145 | preserve | 1116-1124 | 1116-1124 | T65 | patients | PatientOrDisabledGroup | 1,116 | 1,124 | A9 | RESULTS: Fasting lactate and pyruvate levels were significantly increased in patients with type 2 diabetes. | 1033-1146 | 1,033 | 1,146 | RESULTS: Fasting lactate and pyruvate levels were significantly increased in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 148-152 | 148-152 | T15 | with | PROCESS_OF | 148 | 152 | preserve | 153-174 | 166-174 | T11 | type 2 diabetes | DiseaseOrSyndrome | 153 | 174 | preserve | 139-147 | 139-147 | T10 | patients | PatientOrDisabledGroup | 139 | 147 | A10 | alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. | 0-175 | 0 | 175 | alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1392-1404 | 1395-1404 | T97 | LA treatment | ISA | 1,392 | 1,404 | preserve | 1392-1394 | 1392-1394 | T90 | LA | OrganicChemical | 1,392 | 1,394 | preserve | 1395-1404 | 1395-1404 | T91 | treatment | TherapeuticOrPreventiveProcedure | 1,395 | 1,404 | A11 | LA treatment was associated with increased SG in both diabetic groups (lean 1.28 +/- 0.14 to 1.93 +/- 0.13; obese 1.07 +/- 0.11 to 1.53 +/- 0.08 x 10(-2) min-1, P < 0.05). | 1392-1575 | 1,392 | 1,575 | @SUBJECT$ @PREDICAT$ @OBJECT$ was associated with increased SG in both diabetic groups (lean 1.28 +/- 0.14 to 1.93 +/- 0.13; obese 1.07 +/- 0.11 to 1.53 +/- 0.08 x 10(-2) min-1, P < 0.05). |
Fact | preserve | 577-581 | 577-581 | T35 | with | PROCESS_OF | 577 | 581 | preserve | 582-604 | 596-604 | T33 | type 2 diabetes | DiseaseOrSyndrome | 582 | 604 | preserve | 568-576 | 568-576 | T32 | patients | PatientOrDisabledGroup | 568 | 576 | A12 | OBJECTIVE: We examined the effect of lipoic acid (LA), a cofactor of the pyruvate dehydrogenase complex (PDH), on insulin sensitivity (SI) and glucose effectiveness (SG) and on serum lactate and pyruvate levels after oral glucose tolerance tests (OGTTs) and modified frequently sampled intravenous glucose tolerance tests (FSIGTTs) in lean (n = 10) and obese (n = 10) patients with type 2 diabetes. | 176-605 | 176 | 605 | OBJECTIVE: We examined the effect of lipoic acid (LA), a cofactor of the pyruvate dehydrogenase complex (PDH), on insulin sensitivity (SI) and glucose effectiveness (SG) and on serum lactate and pyruvate levels after oral glucose tolerance tests (OGTTs) and modified frequently sampled intravenous glucose tolerance tests (FSIGTTs) in lean (n = 10) and obese (n = 10) @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1873-1890 | 1882-1890 | T134 | diabetic patients | PROCESS_OF | 1,873 | 1,890 | preserve | 1873-1881 | 1873-1881 | T125 | diabetic | Finding | 1,873 | 1,881 | preserve | 1882-1890 | 1882-1890 | T126 | patients | PatientOrDisabledGroup | 1,882 | 1,890 | A14 | CONCLUSIONS: Treatment of lean and obese diabetic patients with LA prevents hyperglycemia-induced increments of serum lactate and pyruvate levels and increases SG. | 1826-2002 | 1,826 | 2,002 | CONCLUSIONS: Treatment of lean and obese @SUBJECT$ @PREDICAT$ @OBJECT$ with LA prevents hyperglycemia-induced increments of serum lactate and pyruvate levels and increases SG. |
Fact | preserve | 0-27 | 18-27 | T13 | alpha-Lipoic acid treatment | USES | 0 | 27 | preserve | 18-27 | 18-27 | T2 | treatment | TherapeuticOrPreventiveProcedure | 18 | 27 | preserve | 0-17 | 13-17 | T1 | alpha-Lipoic acid | OrganicChemical | 0 | 17 | A15 | alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. | 0-175 | 0 | 175 | @OBJECT$ @PREDICAT$ @SUBJECT$ decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. |
Fact | preserve | 1891-1895 | 1891-1895 | T135 | with | USES | 1,891 | 1,895 | preserve | 1839-1848 | 1839-1848 | T123 | Treatment | TherapeuticOrPreventiveProcedure | 1,839 | 1,848 | preserve | 1896-1898 | 1896-1898 | T127 | LA | OrganicChemical | 1,896 | 1,898 | A16 | CONCLUSIONS: Treatment of lean and obese diabetic patients with LA prevents hyperglycemia-induced increments of serum lactate and pyruvate levels and increases SG. | 1826-2002 | 1,826 | 2,002 | CONCLUSIONS: @SUBJECT$ of lean and obese diabetic patients @PREDICAT$ @OBJECT$ prevents hyperglycemia-induced increments of serum lactate and pyruvate levels and increases SG. |
Fact | preserve | 1257-1261 | 1257-1261 | T79 | with | PROCESS_OF | 1,257 | 1,261 | preserve | 1262-1284 | 1276-1284 | T77 | type 2 diabetes | DiseaseOrSyndrome | 1,262 | 1,284 | preserve | 1248-1256 | 1248-1256 | T76 | patients | PatientOrDisabledGroup | 1,248 | 1,256 | A20 | These metabolites did not exceed elevated fasting concentrations after glucose loading in lean patients with type 2 diabetes. | 1147-1285 | 1,147 | 1,285 | These metabolites did not exceed elevated fasting concentrations after glucose loading in lean @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 0-27 | 18-27 | T12 | alpha-Lipoic acid treatment | ISA | 0 | 27 | preserve | 0-17 | 13-17 | T1 | alpha-Lipoic acid | OrganicChemical | 0 | 17 | preserve | 18-27 | 18-27 | T2 | treatment | TherapeuticOrPreventiveProcedure | 18 | 27 | A21 | alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. | 0-175 | 0 | 175 | @SUBJECT$ @PREDICAT$ @OBJECT$ decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. |
Fact | preserve | 133-147 | 139-147 | T14 | obese patients | PROCESS_OF | 133 | 147 | preserve | 133-138 | 133-138 | T9 | obese | DiseaseOrSyndrome | 133 | 138 | preserve | 139-147 | 139-147 | T10 | patients | PatientOrDisabledGroup | 139 | 147 | A23 | alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. | 0-175 | 0 | 175 | alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and @SUBJECT$ @PREDICAT$ @OBJECT$ with type 2 diabetes. |
Fact | preserve | 1788-1805 | 1797-1805 | T120 | diabetic patients | PROCESS_OF | 1,788 | 1,805 | preserve | 1788-1796 | 1788-1796 | T115 | diabetic | Finding | 1,788 | 1,796 | preserve | 1797-1805 | 1797-1805 | T116 | patients | PatientOrDisabledGroup | 1,797 | 1,805 | A24 | Lactate and pyruvate before and after glucose loading were approximately 45% lower in lean and obese diabetic patients after LA treatment. | 1675-1825 | 1,675 | 1,825 | Lactate and pyruvate before and after glucose loading were approximately 45% lower in lean and obese @SUBJECT$ @PREDICAT$ @OBJECT$ after LA treatment. |
Fact | preserve | 1812-1824 | 1815-1824 | T121 | LA treatment | USES | 1,812 | 1,824 | preserve | 1815-1824 | 1815-1824 | T118 | treatment | TherapeuticOrPreventiveProcedure | 1,815 | 1,824 | preserve | 1812-1814 | 1812-1814 | T117 | LA | OrganicChemical | 1,812 | 1,814 | A25 | Lactate and pyruvate before and after glucose loading were approximately 45% lower in lean and obese diabetic patients after LA treatment. | 1675-1825 | 1,675 | 1,825 | Lactate and pyruvate before and after glucose loading were approximately 45% lower in lean and obese diabetic patients after @OBJECT$ @PREDICAT$ @SUBJECT$ . |